11th International Congress on Drug Therapy in HIV Infection, 11-15 November 2012, Glasgow
Oral
1 Temporal Changes and Regional Differences in Treatment Uptake of Hepatitis C Therapy in EuroSIDA. D Grint, L Peters, C Schwarze-Zander, M Beniowski, C Pradier, M Battegay, D Jetovic, V Soriano, JD Lundgren, JK Rockstroh, O Kirk, A Mocroft for EuroSIDA in EuroCoord.
presentation
2 CD4 count and viral load specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. A Mocroft, A Phillips, J Gatell, A Horban, B Ledergerber, K Zilmer, D Jevtovic, F Maltez, O Kirk, J Lundgren et al for the EuroSIDA study in EuroCoord.
presentation
3 Increases in acute hepatitis C (HCV) incidence across Europe: which regions and patient groups are affected? JK Rockstroh, D Grint, C Boesecke, V Soriano, JD Lundgren, A d'Arminio Monforte, VM Mitsura, O Kirk, A Mocroft and L Peters for EuroSIDA in EuroCoord.
presentation
4 Immuno-virological discordance (ID) is associated with a higher frequency of fatal and non-fatal AIDS and non-AIDS. A Zoufaly, A Cozzi-Lepri, O Kirk, JD Lundgren, P Reiss, D Jetovic, L Machala, R Zangerle, A Mocroft, J van Lunzen on behalf of EuroSIDA in EuroCoord.
presentation
5 Advanced chronic kidney disease, end-stage renal disease and renal death in HIV-positive individuals in Europe. L Ryom, O Kirk, JD Lundgren, C Pedersen, P Reiss, S De Wit, S Buzunova, J Gasiorowski, JM Gatell and A Mocroft on behalf of EuroSIDA in EuroCoord.
presentation
Poster
1 Impact of antiretroviral therapy (ART), viraemia and immunosuppression on lipid levels: the D:A:D Study. DA Kamara, C Sabin, P Reiss, M Rickenbach, C Smith, S De Wit, M Law, A Mocroft, C Pradier, JD Lundgren.
presentation
XXXIII Nordic Congress in Clinical Chemistry, June 12th - 15th 2012, Reykjavik
Oral
Procalcitonin use in infections in different settings - The need for clinical trials. Jens-Ulrik Jensen.
52nd ICAAC, San Francisco, September 2012
Oral
The Time Course Of Development And Impact From Viral Resistance Against Ganciclovir In Cytomegalovirus Infection Complicating Course After Transplantation. C da Cunha-Bang.
Poster
Evaluation of novel programme aimed at reducing the risk of severe viral infections including cytomegalovirus, following solid organ transplantation. C da Cunha-Bang, N Kirkby, SS Sørensen, M Iversen, H Sengeløv, A Rasmussen, F Gustafson, J Hilsted, J Kjær, RS Brandt, C Matthews, L Peters, O Kirk, J Grarup, JD Lundgren. presentation
XIX International AIDS Conference, Wash DC, July 2012
Oral
1 Characteristics of individuals with HIV presenting late for care across Europe. Jens D. Lundgren for the late presenters working group of COHERE in EuroCoord.
presentation (724 KB)
2 Trends over time in underlying causes of death in the D:A:D Study from 1999 to 2011. CJ Smith, L Ryom, R Weber, P Morlat, C Pradier, P Reiss, J Kowalska, N Friis-Møller, AN Phillips, CA Sabin, JD Lundgren for the D:A:D Study Group.
presentation
3 The START Trial: On the shoulders of SMART. JD Lundgren.
presentation
Poster
1 Factors associated with elevated D-dimer levels in HIV-positive individuals. A Borges, J O'Connor, A Phillips, J Baker, M Vjecha, M Losso, H Klinker, G Lopardo, I Williams, JS Lundgren, for the INSIGHT SMART, ESPRIT and SILCAAT Study Groups.
poster
XIX International Workshop on Co-morbidities and Adverse Drug Reactions in HIV, Wash DC, July 2012
Oral
1 Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. A Borges, MJ Silverberg, D Wentworth, A Grulich, G Fätkenheurer, R Mitsuyasu, G Tambussi, C Sabin, J Neaton, JD Lundgren, for the INSIGHT SMART, ESPRIT and SILCAAT Study Groups.
19th Conference on Retroviruses and Opportunistic Infections, Seattle, March 2012
Oral
1 Non-AIDS defining malignancies (NADM) and immunosuppression: The D:A:D study. Signe W. Worm, M Bower, P Reiss, A Grulich, E Fontas, F Bonnet, G Faetkenheuer, M Law, A Phillips, HJ Furrer, W El-Sadr, O Kirk, L Ryom, D Abrams, A D’Arminio Monforte, S De Wit, C Sabin, JD Lundgren on behalf of the D:A:D study group.
Presentation (197 kb)
Poster
1 Exposure to Antiretrovirals (ARVs) and the Risk of Renal Impairment among HIV+ Persons with Normal Baseline Renal Function: the D:A:D Study. L Ryom, A Mocroft, SW Worm,, DA Kamara, P Reiss, M Ross, C Fux, P Morlat, O Moranne, C Smith, O Kirk and JD Lundgren on behalf of the D:A:D study group.
Poster (105 kb)
2 Atazanavir (ATV)-Containing Antiretroviral Treatment is not Associated with an Increased Risk of Cardio- or Cerebro-Vascular Events (CVE) in the D:A:D Study. A d’Arminio Monforte, P Reiss, L Ryom, W El-Sadr, F Dabis, S De Wit, SW Worm, A Phillips, J Lundgren, and C Sabin.
Poster (101 kb)
3 Associations between Markers of Immunosuppression and the Risk of Cardiovascular Disease (CVD): the D:A:D Study C Sabin, SW Worm, M Law, W El-Sadr, P Reiss, M Bruyand, E Fontas, A d’Arminio Monforte, R Weber, O Kirk, S de Wit, JD Lundgren on behalf of the D:A:D Study Group.
Poster (202 kb)
4 The Effect of Interleukin-2 in HIV-1 Patients with HBV and HCV co-infection: Associations between Fibrosis Biomarkers at Baseline and Clinical Outcomes in the ESPRIT Study L Peters, S Bhagani, M Klein, J Lundgren, N Markowitz, V Soriano, J Rockstroh, J Neaton, W Stohr, D Dunn, M Danta, C Boesecke, P de la Torre, F Zamora, M Landrum, E Page, S Rizza, A Rodger, D Wentworth for the INSIGHT ESPRIT Study Group.
Poster (235 kb)